- Home
- SSTI vs DRUG Comparison
SSTI vs DRUG Comparison
Compare SSTI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTI
- DRUG
- Stock Information
- Founded
- SSTI 1996
- DRUG 2019
- Country
- SSTI United States
- DRUG United States
- Employees
- SSTI N/A
- DRUG N/A
- Industry
- SSTI Computer Software: Prepackaged Software
- DRUG Pharmaceuticals and Biotechnology
- Sector
- SSTI Technology
- DRUG Health Care
- Exchange
- SSTI Nasdaq
- DRUG Nasdaq
- Market Cap
- SSTI 196.6M
- DRUG 233.2M
- IPO Year
- SSTI 2017
- DRUG N/A
- Fundamental
- Price
- SSTI $15.57
- DRUG $27.31
- Analyst Decision
- SSTI Buy
- DRUG Strong Buy
- Analyst Count
- SSTI 8
- DRUG 6
- Target Price
- SSTI $20.38
- DRUG $83.25
- AVG Volume (30 Days)
- SSTI 42.5K
- DRUG 19.6K
- Earning Date
- SSTI 08-05-2025
- DRUG 08-13-2025
- Dividend Yield
- SSTI N/A
- DRUG N/A
- EPS Growth
- SSTI N/A
- DRUG N/A
- EPS
- SSTI N/A
- DRUG N/A
- Revenue
- SSTI $104,970,000.00
- DRUG N/A
- Revenue This Year
- SSTI $11.41
- DRUG N/A
- Revenue Next Year
- SSTI $8.56
- DRUG N/A
- P/E Ratio
- SSTI N/A
- DRUG N/A
- Revenue Growth
- SSTI 7.65
- DRUG N/A
- 52 Week Low
- SSTI $9.33
- DRUG $0.93
- 52 Week High
- SSTI $19.43
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- SSTI 46.30
- DRUG 41.95
- Support Level
- SSTI $15.50
- DRUG $27.69
- Resistance Level
- SSTI $16.85
- DRUG $28.74
- Average True Range (ATR)
- SSTI 0.64
- DRUG 1.29
- MACD
- SSTI -0.04
- DRUG 0.14
- Stochastic Oscillator
- SSTI 20.59
- DRUG 39.29
About SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.